SAN DIEGO–(BUSINESS WIRE)–June 9, 2022–
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the discovery, acquisition, development and commercialization of therapeutics in the areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The article, titled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension”, is currently available online and will be included in a future print edition of the European Respiratory Journalthe flagship scientific journal of the European Respiratory Society.
“We are thrilled to share some of the preclinical underpinnings of the seralutinib program in such a high-impact scientific journal,” said Faheem Hasnain, Co-Founder, President and CEO of Gossamer Bio. “The studies included in the publication are part of the reason that we, along with the broader PAH community, look forward to the first results from the TORREY Phase 2 study in the fourth quarter of this year.”
The article is accessible via a link from the Posters and Publications section of the Gossamer website ( https://www.gossamerbio.com/pipeline/posters-and-publications/ ) or directly via the European Respiratory Journal website (https://erj.ersjournals.com/).
Item Information
- Log:European Respiratory Journal
- Title: Inhaled Seralutinib Shows Potent Efficacy in Pulmonary Arterial Hypertension Models
- DO I: 10.1183/13993003.02356-2021
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the discovery, acquisition, development and commercialization of therapeutic products in the areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to improve and extend the lives of patients suffering from these diseases.
Forward-looking statements
Gossamer cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: expectations regarding the timing of reading data from our clinical studies, including the timing of key results from the Phase 2 TORREY study for seralutinib; the potential benefits of seralutinib based on preclinical data; and the future print publication of the article mentioned here. The inclusion of forward-looking statements should not be taken as a representation by Gossamer that any of its plans will be realized. Actual results may differ from those presented in this press release due to risks and uncertainties inherent in Gossamer’s business, including, but not limited to: potential delays in the initiation, recruitment and completion of clinical trials ; disruption of our operations due to the ongoing COVID-19 pandemic, including clinical trial delays and staffing shortages at clinical sites; the Company’s dependence on third parties for product manufacturing, research and preclinical and clinical testing; the results of preclinical studies and early clinical trials are not necessarily predictive of future results; the success of Gossamer’s clinical trials and preclinical studies for its product candidates; interim results do not necessarily predict final results and one or more of the results may change significantly as the trial continues and more patient data becomes available and following more audit and verification procedures complete; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of our product candidates which may limit their development, regulatory approval and/or commercialization, or which may lead to recalls or product liability claims; Gossamer’s ability to obtain and maintain intellectual property protection for its product candidates; Gossamer’s ability to meet its obligations in collaboration agreements with third parties or agreements under which it licenses intellectual property rights to third parties; Gossamer can use his capital resources sooner than expected; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and in all subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Gossamer undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220609005043/en/
CONTACT: For investors and the media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
KEYWORD: CALIFORNIA EUROPE UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH PHARMACEUTICAL SCIENCE CARDIOLOGY BIOTECHNOLOGY
SOURCE: Gossamer Bio, Inc.
Copyright BusinessWire 2022.
PUBLICATION: 06/09/2022 08:30 / DISK: 06/09/2022 08:32
http://www.businesswire.com/news/home/20220609005043/en
